TY - JOUR
T1 - Collaborative depression care sensitive to the needs of underserved patients with cancer
T2 - Feasibility, acceptability and outcomes
AU - Price, Sarah
AU - Hamann, Heidi A.
AU - Halaby, Laila
AU - Trejo, Juanita
AU - Rogers, Fernanda Corella
AU - Weihs, Karen
N1 - Publisher Copyright: © 2023 Taylor & Francis Group, LLC.
PY - 2024
Y1 - 2024
N2 - Purpose: A single-arm trial evaluated the feasibility, acceptability, and outcomes of COPE-D, a collaborative care intervention for underserved cancer patients with depression. Methods: Bilingual (Spanish and English) care managers provided counseling and/or medication management in consultation with physicians. Outcomes were treatment improvement (≥ 5-point reduction in PHQ-9), treatment response (≥ 50% reduction in PHQ-9), suicidal ideation resolution, and changes in depression (PHQ-9), anxiety (GAD-2), sleep disturbance (PSQI), global mental and physical health (PROMIS), social isolation (PROMIS), and qualitative feedback. Results: 193 patients consented to participate. 165 initiated and 141 completed treatment, with 65% and 56% achieving treatment improvement and response, respectively. Outcomes did not differ by ethnicity (31% Hispanic), cancer stage (71% stages III-IV), income, or education. Suicidal ideation, depression, anxiety, sleep disturbance, and social isolation also improved. Qualitative feedback was largely positive. Conclusion: COPE-D improved depression and quality of life among underserved patients, with acceptable retention rates.
AB - Purpose: A single-arm trial evaluated the feasibility, acceptability, and outcomes of COPE-D, a collaborative care intervention for underserved cancer patients with depression. Methods: Bilingual (Spanish and English) care managers provided counseling and/or medication management in consultation with physicians. Outcomes were treatment improvement (≥ 5-point reduction in PHQ-9), treatment response (≥ 50% reduction in PHQ-9), suicidal ideation resolution, and changes in depression (PHQ-9), anxiety (GAD-2), sleep disturbance (PSQI), global mental and physical health (PROMIS), social isolation (PROMIS), and qualitative feedback. Results: 193 patients consented to participate. 165 initiated and 141 completed treatment, with 65% and 56% achieving treatment improvement and response, respectively. Outcomes did not differ by ethnicity (31% Hispanic), cancer stage (71% stages III-IV), income, or education. Suicidal ideation, depression, anxiety, sleep disturbance, and social isolation also improved. Qualitative feedback was largely positive. Conclusion: COPE-D improved depression and quality of life among underserved patients, with acceptable retention rates.
KW - Patient Health Questionnaire Anxiety and Depression Scale
KW - cancer
KW - depression
KW - oncology
KW - psychosocial intervention
KW - sleep
UR - http://www.scopus.com/inward/record.url?scp=85162648912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162648912&partnerID=8YFLogxK
U2 - 10.1080/07347332.2023.2224314
DO - 10.1080/07347332.2023.2224314
M3 - Article
SN - 0734-7332
VL - 42
SP - 90
EP - 112
JO - Journal of Psychosocial Oncology
JF - Journal of Psychosocial Oncology
IS - 1
ER -